05:01 AM EDT, 05/13/2026 (MT Newswires) -- Eli Lilly (LLY) said late Tuesday people with obesity maintained weight loss long term with either Foundayo or lower-dose Zepbound in two late-phase trials after moving from higher doses of injectable incretin therapy.

In one of the studies, participants who switched from a maximum-tolerated dose of Wegovy to Foundayo maintained all but 0.9 kilogram of their previously achieved weight loss on average after one year.

In both the trials, participants who switched from Zepbound MTD to Foundayo or lowered the dose of Zepbound to 5 mg, respectively, maintained all but 5 kg and 5.6 kg of their previous weight loss on average following one year, the company said.

Foundayo and Zepbound showed safety profiles consistent with previous phase 3 studies across both trials, Lilly said.